lifestyle.spaziotribu.net

Author: OSE Immunotherapeutics

OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting

April 15, 2026
OSE Immunotherapeutics Evolves its Leadership Team

April 14, 2026